PMID- 11315624
OWN - NLM
STAT- MEDLINE
DCOM- 20010503
LR  - 20190921
IS  - 0945-6317 (Print)
IS  - 0945-6317 (Linking)
VI  - 438
IP  - 3
DP  - 2001 Mar
TI  - Nasal CD56 positive small round cell tumors. Differential diagnosis of 
      hematological, neurogenic, and myogenic neoplasms.
PG  - 271-9
AB  - CD56-positive nasal and nasal-type natural killer (NK)/T-cell lymphoma is now a 
      well-defined disease entity. Rare cases of blastic NK-cell lymphoma positive for 
      CD56 have been recently reported. However, CD56 expression is also identified in 
      several types of non-hematopoietic small round cell tumors in which lymphoma is 
      included as a differential consideration. Here, we present nine cases of CD56+ 
      small round cell tumors of histological origin unrelated to nasal NK/T-cell 
      lymphoma. Eight of the nine cases presented as solid tumors of the sinonasal 
      region. Clinical, histological, ultrastructural, and immunohistochemical 
      examination and gene analysis for T-cell receptor (TcR) and immunoglobulin heavy 
      chain (IgH) genes and in situ hybridization (ISH) for Epstein-Barr virus (EBV) 
      were performed. Two cases presented with features consistent with blastic NK-cell 
      lymphoma or lymphoblastic lymphoma of NK-cell phenotype. These cases showed 
      features of lymphoblastic lymphoma, phenotypes of sCD3-, cCD3+, CD45+, CD56+, 
      TdT+, and human leukocyte antigen (HLA)-DR+, germline of IgH and TcR genes, and 
      EBV negative reactivity. One case had myeloid/NK-precursor acute 
      leukemia/lymphoma with a phenotype of CD13+, CD33+, CD34+, CD56+, and MPO-. Three 
      cases were neurogenic, including one case of olfactory neuroblastoma and two of 
      primitive neuroectodermal tumors (PNET). It was difficult to differentiate CD56+ 
      PNET from blastic NK-cell lymphoma, especially when only paraffin-embedded 
      sections were available. Myogenic markers, such as HHF35, alpha-sarcomeric actin, 
      and desmin, were positive in three cases of rhabdomyosarcomas. Our findings 
      suggest that as CD56 is used more routinely as a marker in immunohistochemical 
      staining, the differential diagnosis of extranodal lymphohematological 
      malignancies and small round cell tumors will become more complicated.
FAU - Liu, Q
AU  - Liu Q
AD  - Department of Pathology, School of Medicine, Fukuoka University, Nanakuma 7-45-1, 
      Jonanku, Fukuoka 814-01, Japan.
FAU - Ohshima, K
AU  - Ohshima K
FAU - Sumie, A
AU  - Sumie A
FAU - Suzushima, H
AU  - Suzushima H
FAU - Iwasaki, H
AU  - Iwasaki H
FAU - Kikuchi, M
AU  - Kikuchi M
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Germany
TA  - Virchows Arch
JT  - Virchows Archiv : an international journal of pathology
JID - 9423843
RN  - 0 (CD56 Antigen)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - CD56 Antigen/*analysis
MH  - Child, Preschool
MH  - Diagnosis, Differential
MH  - Female
MH  - Humans
MH  - Infant
MH  - Killer Cells, Natural/*immunology
MH  - Lymphoma, T-Cell/*diagnosis/immunology/pathology
MH  - Male
MH  - Middle Aged
MH  - Neuroectodermal Tumors, Primitive/diagnosis
MH  - Nose Neoplasms/*diagnosis/immunology/pathology
EDAT- 2001/04/24 10:00
MHDA- 2001/05/05 10:01
CRDT- 2001/04/24 10:00
PHST- 2001/04/24 10:00 [pubmed]
PHST- 2001/05/05 10:01 [medline]
PHST- 2001/04/24 10:00 [entrez]
AID - 10.1007/s004280000326 [doi]
PST - ppublish
SO  - Virchows Arch. 2001 Mar;438(3):271-9. doi: 10.1007/s004280000326.